Drugs / SAR448851
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07688213 | Jul 2026 → Jul 2029 expected | Alzheimer disease | Sanofi | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR448851 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07688213 ↗ |
| Route | Oral | “Route of administration: Oral” NCT07688213 ↗ |